



# From Science to Practice: Optimizing Lipid Lowering Therapies for Cardiovascular Risk Reduction

Amgen Symposium  
WCIM 2024 in Prague  
Congress Hall  
Nov. 1st 2024 from 1.00 pm to 2.30 pm

Introduction

Richard Češka

CV Risk Reduction with Lipid Lowering:  
When and How?

Lale Tokgözoğlu

The Power of Low LDL-C:  
Who Benefits Most and How Low is Enough?

Michal Vrablík

From Research to Clinical Settings:  
PCSK9i Real Life Experience in Europe

Alberto Zambon

Panel discussion

ALL

## SPEAKERS

*“New lipid treatments represent an effective option to improve prognosis of the CVD patients.”*



**RICHARD ČEŠKA**  
MD PHD FACP FEFIM

*Professor at the Faculty of Medicine, Charles University Prague, Czech Republic.*



**S. LALE TOKGÖZOĞLU**  
MD FACC FESC

*Professor at the Hacettepe University, Department of Cardiology, Ankara, Türkiye and past – president of the European Atherosclerosis Society.*

*“CV risk reduction through lipid-lowering is a cornerstone of preventive medicine, with modern lipid guidelines recommending a personalized approach to lipid management with a “treat to target” approach.”*

*“Long term low LDL-C levels are likely the safest and most effective measure to avoid ASCVD event.”*



**MICHAL VRABLÍK**  
MD PHD

*Professor of Internal Medicine at the 1st Faculty of Medicine, Charles University in Prague, Czech Republic.*



**ALBERTO ZAMBON**  
MD PHD

*Associate professor of Medicine at the University of Padova, Dept. Of Medicine, Padova, Italy.*